EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Cancer Immuno Perspectives · 2025

DOI: 10.70996/cip.00009 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Immuno Perspectives, 2025.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background:Platinum-based chemotherapy has long been the standard first-line treatment for advanced nonsmall cell lung cancer (NSCLC), but its efficacy remains limited.Immune checkpoint inhibitors (ICIs) combined with chemotherapy represent a novel therapeutic strategy; however, its pooled efficacy and safety across different populations and pathological subtypes require comprehensive validation.Objective:To systematically evaluate the efficacy and safety of first-line ICI plus chemotherapy versus chemotherapy alone in patients with advanced NSCLC, and to explore differences in therapeutic effects between squamous and non-squamous subtypes.Methods:We systematically searched PubMed, Embase, the Cochrane Library, and ClinicalTrials.govfrom inception to October 2024 for randomized controlled trials (RCTs) comparing first-line ICI plus chemotherapy with chemotherapy alone in advanced NSCLC.Primary outcomes were overall survival (OS) and progression-free survival (PFS).Subgroup analyses were performed by pathological subtype.Heterogeneity was assessed using I² statistics, and publication bias was evaluated via funnel plots and Egger's test.The Cochrane Risk of Bias Tool (RoB 2.0) was used for quality assessment.Statistical analyses were performed using Stata 17.0.Results:A total of 6 RCTs involving 3342 patients were included, with 1856 patients in the ICI + chemotherapy group and 1486 patients in the chemotherapy alone group.Meta-analysis results showed that compared with chemotherapy alone, ICI + chemotherapy significantly improved OS (hazard ratio [HR] = 0.64, 95% confidence interval [CI]: 0.52-0.79,P

Zitieren

APA

(2025). First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cancer Immuno Perspectives. https://doi.org/10.70996/cip.00009

Vancouver

First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cancer Immuno Perspectives. 2025. doi:10.70996/cip.00009

BibTeX
@article{euvimed2025,
  title = {First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis},
  journal = {Cancer Immuno Perspectives},
  year = {2025},
  doi = {10.70996/cip.00009}
}
Kostenlos starten →